Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
Innate Pharma is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. These novel drugs consist of monoclonal antibodies that can activate the innate immune system.
Backed by Gilde as an investor, Innate Pharma has advanced its product pipeline to the clinical development stage and built strong commercial partnerships with Novo Nordisk and Bristol-Myers Squibb.
Innate Pharma operates from Marseille, France, and was successfully listed at Euronext Paris (IPH) after its IPO in 2006.
More Innate Pharma news
Innate Pharma signs Global License Agreement with BMS, potential deal value up to $465 million
INNATE PHARMA initiates collaboration with Celgene
Innate Pharma reports positive phase IIa in type C viral hepatitis
INNATE PHARMA Swaps Products with NOVO NORDISK A/S to Obtain full Commercial Rights
Venture&Growth
Acacia Pharma
Belgian Therapeutics company commercializing supportive care products to treat side effects of medical procedures.
Venture&Growth
Amphista Therapeutics
Amphista Therapeutics is a UK-based company creating first-class therapeutics to selectively degrade and remove disease-causing proteins by harnessing the body’s natural processes. It’s next generation targeted protein degradation TPD-based medicines leverage novel mechanisms that make use of a wider range
Venture&Growth
Axonics Modulation Technologies
US MedTech company focused on neuromodulation.
